Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current and future management of Ph/BCR-ABL positive ALL.
Maino E, Sancetta R, Viero P, Imbergamo S, Scattolin AM, Vespignani M, Bassan R. Maino E, et al. Among authors: vespignani m. Expert Rev Anticancer Ther. 2014 Jun;14(6):723-40. doi: 10.1586/14737140.2014.895669. Epub 2014 Mar 10. Expert Rev Anticancer Ther. 2014. PMID: 24611626 Review.
Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy.
Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F, Scimè R, Lombardini L, Viscoli C, Rambaldi A; Gruppo Italiano Trapianto Midollo Osseo (GITMO); Gruppo Italiano Trapianto Midollo Osseo GITMO. Girmenia C, et al. Bone Marrow Transplant. 2015 Feb;50(2):282-8. doi: 10.1038/bmt.2014.231. Epub 2014 Oct 13. Bone Marrow Transplant. 2015. PMID: 25310302 Free article.
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R, Pogliani E, Lerede T, Fabris P, Rossi G, Morandi S, Casula P, Lambertenghi-Deliliers G, Vespignani M, Izzi T, Coser P, Corneo G, Barbui T. Bassan R, et al. Among authors: vespignani m. Haematologica. 1999 Dec;84(12):1088-93. Haematologica. 1999. PMID: 10586210 Clinical Trial.
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups.
Bassan R, Pogliani E, Casula P, Rossi G, Fabris P, Morandi S, Lambertenghi-Deliliers G, Vespignani M, Lerede T, Rambaldi A, Borleri G, Spedini P, Cortelezzi A, Izzi T, Coser P, Broccia G, Corneo G, Barbui T. Bassan R, et al. Among authors: vespignani m. Hematol J. 2001;2(2):117-26. doi: 10.1038/sj/thj/6200091. Hematol J. 2001. PMID: 11424004 Clinical Trial.
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M, et al. Sertoli MR, et al. Among authors: vespignani m. J Clin Oncol. 1994 Jul;12(7):1366-74. doi: 10.1200/JCO.1994.12.7.1366. J Clin Oncol. 1994. PMID: 7517442 Clinical Trial.
Impact of interferon at induction chemotherapy and maintenance treatment for multiple myeloma. Preliminary results of a multicenter study by the Italian non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG).
Capnist G, Vespignani M, Spriano M, Damasio E, Craviotto L, Rizzoli V, Contu A, Olmeo N, Tedeschi L, Fabris P, et al. Capnist G, et al. Among authors: vespignani m. Acta Oncol. 1994;33(5):527-9. doi: 10.3109/02841869409083930. Acta Oncol. 1994. PMID: 7522487 Clinical Trial.
44 results